Presented by Dr. John MacDougall this webinar presents Mouse Clinical Trials (MCT) using PDX models, and will help to guide you through the process of determining which MCT best suits the specific needs of any given drug development program.

Improve your model selection decision for any immuno-oncology study by exploring the immunocompetent model types within this white paper. Learn more about the features, limitations and major uses of each type and how to apply them to your next study.

Make better go/no-go decisions with CRISPR Engineered Cell Line Services.

CrownBio provides efficient, cost-effective gene editing services using licensed CRISPR/Cas9 technology. Our experts can generate knock in and knockout cell lines with vector controls that are tailored to meet your specific needs and help you advance your preclinical drug development programs.

Poster: Humanized CD137 Models for Preclinical Drug Development

Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)

Presented by Dr. Keefe Chng and Dr Judith Gorski this webinar will help guide you through a study design process that will enable the greatest opportunity to generate robust, high-quality data, that gives maximum confidence to select new drug candidates and regulatory submissions.

Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)

Watch this scientific webinar presented by Dr. Mark Yorek, Professor of Medicine at University of Iowa and Associate Chief of Staff for Research at Iowa City VA. He will discuss the challenges in modeling diabetic neuropathy and how the use of improved translational rodent models can impact Diabetes and Obesity pre-clinical studies.

1820-P: The Depletion of Peripheral NK Cells and NK T Lymphocytes in a Spontaneously Diabetic Non-Human Primate Model

1881-P: Rhythmic Differences of Blood Glucose Circadian between Normoglycemic and Diabetic Non-Human Primates

Join our webinar to discover the wide range of in vivo immuno-oncology preclinical models available, and what to consider when choosing the correct model for your studies. Learn how current models are being used to progress combination regimens, including dual immunotherapies, and I/O agents plus other treatment modalities.

This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.

Join our webinar to discover the development and utility of CrownBio's unique continuum of translational platforms modeling diabetes and metabolic syndrome pathophysiology, progression, and complications. Learn how these platforms are predicting the efficacy and safety of anti-diabetic therapies in humans.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.